Cardiac depressant factors in renal disease

Circulation

Volumn 87, Issue 5 SUPPL., 1993, Pages

  Horl W H ^a   Riegel, W ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Cardiac depressant factor; Cardiomyopathies; Renal disease; Renal failure, acute; Renal failure, chronic

Indexed keywords

BETA ADRENERGIC RECEPTOR;

ACUTE KIDNEY FAILURE; CARDIOMYOPATHY; CARDIOTOXICITY; CARNITINE DEFICIENCY; CHRONIC KIDNEY FAILURE; DIALYSIS; HEART DISEASE; HEART MUSCLE FIBROSIS; HUMAN; HYPERPARATHYROIDISM; KIDNEY DISEASE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; REVIEW; SEPSIS; UREMIA;

ACETATES; ANIMAL; HEART; HUMAN; IONS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MULTIPLE ORGAN FAILURE; MYOCARDIAL DISEASES; MYOCARDIUM; PARATHYROID HORMONES; RECEPTORS, ADRENERGIC, BETA; RENAL DIALYSIS; UREMIA;

EID: 0027214769     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Mall G, Huther W, Schneider J, Lundin P, Ritz E: Diffuse inter-myocardiocytic fibrosis in uremic patients. Nephrol Dial Transplant 1990;5:39-44
2. Geerlings W, Tufveson G, Brunner FP, Ehrich JHH, Fassbinder W, Landais P, Mallick N, Margreiter R, Raine AEG, Rizzoni G, Selwood N: Combined report on regular dialysis and transplantation in Europe, XXI, 1990. Nephrol Dial Transplant 1991;6(suppl 4):5-29
3. Kirkendol PL, Devia CJ, Bower JD, Holbert RD: A comparison of the cardiovascular effects of sodium acetate, sodium bicarbonate and other potential sources of fixed base in hemodialysate solutions. Trans Am Soc Artif Intern Organs 1977;23:399-405
4. Mansell MA, Crowther A, Laker MF, Wing AJ: The effect of hyperacetatemia on cardiac output during regular hemodialysis. Clin Nephrol 1982;18:130-134
5. Drücke T, Fleury I, Toure Y, De Vernejoul P, Fauchet M, Lesourd P, LePailleur C, Crosnier J: Effect of parathyroidectomy on left-ventricular function in hemodialysis patients. Lancet 1980;1: 112-114
6. Bogin E, Massry SG, Harary I: Effect of parathyroid hormone on heart cells. J Clin Invest 1981;67:1215-1227
7. Lhoste F, Drücke T, Larus S, Boissier JR: Cardiac interaction between parathyroid hormone, β-adrenoceptor, and verapamil in the guinea pig in vitro. Clin Exp Pharmacol Physiol 1980;7:377-385
8. Baczynski R, Massry SG, Kohan R, Magott M, Saglikes Y, Brautbar N: Effect of parathyroid hormone on myocardial energy metabolism in the rat. Kidney Int 1985;27:718-725
9. Bogin E, Levi J, Harary I, Massry SG: Effects of parathyroid hormone on oxidative phosphorylation of heart mitochondria. Miner Electrolyte Metab 1982;7:151-156
10. Smogorzewski M, Perna AF, Borum PR, Massry SG: Fatty acid oxidation in the myocardium: Effects of parathyroid hormone and chronic renal failure. Kidney Int 1988;34:797-803
11. Gafter U, Battler A, Eldar M, Zevin D, Neufeld HN, Levi J: Effect of hyperparathyroidism on cardiac function in patients with end-stage renal disease. Nephron 1985;41:30-33
12. London GM, De Vernejoul M-C, Fabiani F, Marchais SJ, Guerin AP, Metivier F, London AM, Llach F: Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int 1987;32:900-907
13. Rostand SG, Sanders C, Kirk KA, Rutsky EA, Fraser RG: Myocardial calcification and cardiac dysfunction in chronic renal failure. Am J Med 1988;85:651-657
14. Hüting J, Kramer W, Wizemann V, Schütterle G: Effects of secondary hyperparathyroidism on left ventricular hypertrophy and function in patients on different renal replacement therapies, in Timio S, Wizemann V (eds): Cardionephrology. Milan, Wichtig Editore, 1991, pp 119-122
15. Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre P, Guttmann RD: Left ventricular hypertrophy in end-stage renal disease. Nephron 1988;48:107-115
16. Rambausek M, Ritz E, Mall G, Mehls O, Katus H: Myocardial hypertrophy in rats with renal insufficiency. Kidney Int 1985;28: 775-782
17. Feldman AM, Fionsh B, Zahka KG, Onyang P, Banghman KL: Congestive cardiomyopathy in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1988;11:76-79
18. Wanner C, Hörl WH: Carnitine abnormalities in patients with renal insufficiency: Pathophysiological and therapeutical aspects. Nephron 1988;50:89-102
19. Perna AF, Smogorzewski M, Massry SG: Effects of verapamil on the abnormalities in fatty acid oxidation of myocardium. Kidney Int 1989;36:453-457
20. Coratelli P, Buongiorno E, Petrarulo F, Corciulo R, Giannattasio M, Passavanti G, Antonelli G: Pathogenetic aspects of uremic cardiomyopathy. Miner Electrolyte Metab 1989;15:246-253
21. Weber KT, Janicki JS, Campbell C, Replogle R: Pathophysiology of acute and chronic cardiac failure. Am J Cardiol 1987;60:3C-9C
22. Weber KT, Clark WA, Janicki JS, Shroff SG: Physiologic versus pathologic hypertrophy and the pressure-overloaded myocardium. J Cantiovasc Pharmacol 1987;10(suppl 6):S37-S50
23. Hüting J, Kramer W, Charra B, Laurent G, Wizemann V, Schütteric G: Asymmetric septal hypertrophy and left atrial dilatation in patients with end-stage renal disease on long-term hemodialysis. Clin Nephrol 1989;32:276-283
24. Kramer W, Thormann J, Hüting J, Schlepper M, Wizemann V: Left ventricular dysfunction in terminal renal insufficiency: Does this indicate "uremic cardiomyopathy"? (abstract) Circulation 1988; 78(suppl II):II-364
25. Parfrey PS, Griffiths SM, Harnett JD, Taylor R, King A, Hand J, Barre PE: Outcome of congestive heart failure, dilated cardiomyopathic hyperkinetic disease, and ischaemic heart disease in dialysis patients. Am J Nephrol 1990;10:213-221
26. Parfrey PS, Harnett JD, Griffiths SM, Gault MH, Barre PE: Congestive heart failure in dialysis patients. Arch Intern Med 1988;148: 1519-1525
27. Burt RK, Gupta-Burt S, Suki WN, Barcenas CG, Ferguson JF, Van Buren CT: Reversal of left ventricular dysfunction after renal transplantation. Ann Intern Med 1989;111:635-640
28. Ratge D, Augustin R, Wisser H: Catecholamines, renin, aldosterone and arterial pressure in patients on chronic hemodialysis treatment. Int J Artif Organs 1983;6:255-260
29. 2-adrenoceptor-stimulated potassium uptake in end-stage renal disease. J Clin Pharmacol 1987;27:628-631
30. Henrich WL, Katz FH, Molinoff PB, Schrier RW: Competitive effects of hypokalemia and volume depletion on plasma renin activity, aldosterone and catecholamine concentrations in hemodialysis patients. Kidney Int 1977;12:279-284
31. Botey A, Gaya J, Montolin I: Postsynaptic adrenergic unresponsiveness in hypotensive dialysis patients. Proc Eur Dial Transplant Assoc 1981;18:586-591
32. Campese VM, Romoff MS, Levitan D: Mechanisms of autonomic nervous system dysfunction in uremia. Kidney Int 1981;20:246-253
33. Martinez Vea A, Montoliu J, Andreu L, Torras A, Gaya J, López-Pedret J, Revert L: Beta adrenergic modulation of extrarenal potassium disposal in terminal uraemia. Proc Eur Dial Transplant Assoc 1982;19:756-760
34. Brodde OE, Daul A: Alpha- and beta-adrenoceptor changes in patients on maintenance hemodialysis. Contrib Nephrol 1984;41: 99-107
35. Meggs LG, Ben-Ari J, Gammon D, Choundhury M, Goldman AI: Adaptive myocardial hypertrophy in the renal ablation model. Am J Hypenens 1990;3:33-38
36. Meggs LG, Ben-Ari I, Gammon D, Choundhury N, Goldman AI: Effect of chronic uremia on the cardiovascular alpha-1 receptor. Life Sci 1986;39:169-179
37. Bobik A, Korner P: Cardiac beta adrenoceptors and adenylate cyclase in normotensive and renal hypertensive rabbits during changes in autonomic activity. Clin Exp Hypertens 1981;3:257-280
38. Freissmuth M, Kraupp O, Hausleithner V, Tuisl E, Schütz W: Alterations of the glomerular β-adrenoceptor-linked adenylate cyclase system in perinephritis hypertension. J Cardiovasc Pharmacol 1986;8:60-66
39. Sahai A, Ganguly PK: Congestive heart failure in diabetes with hypertension may be due to uncoupling of the atrial natriuretic peptide receptor-effector system in the kidney basolateral membrane. Am Heart J 1991;122:164-170
40. Lai KN, Barnden L, Mathew TH: Effect of renal transplantation on left ventricular function in hemodialysis patients. Clin Nephrol 1982;18:74-78
41. Low-Friedrich I, Weisensee D, Bereiter-Hahn J, Schoeppe W: Cultured cardiac myocytes under uremic conditions as a new approach to "uremic myocardiopathy," in Timio S, Wizemann V (eds): Cardionephrology. Milan, Wichtig Editore, 1991, pp 367-370
42. Bernard P, Crest M, Rinaudo J-P, Gallice P, Fournier N, Crevat A, Murisasco A, Saingra S, Frayssinet R: A study of the cardiotoxicity of uremic middle molecules on embryonic chick hearts. Nephron 1982;31:135-140
43. Kimura G, Kojima S, Kawano Y, Imanishi M, Kuramochi M, Omae T: Removal of intracellular waste products by hemofiltration. Am J Kidney Dis 1989;13:226-231
44. Bagdade JD, Subbaiah PV, Bartos D, Bartos F, Campbell RA: Polyamines: An unrecognised cardiovascular risk factor in chronic dialysis? Lancet 1979;1:412-413
45. Cunnion RE, Parrillo JE: Myocardial dysfunction in sepsis. Crit Care Clin 1989;5:99-118
46. Lefer AM, Martin J: Origin of myocardial depressant factor in shock. Am J Physiol 1970;218:1423-1427
47. Greene LJ, Shapanka R, Glenn TM, Lefer AM: Isolation of myocardial depressant factor from plasma of dogs in hemorrhagic shock. Biochim Biophys Acta 1977;491:275-285
48. Carli A, Auclair MC, Bennasayag C, Nunez E: Evidence for an early lipid soluble cardiodepressant factor in rat serum after a sublethal dose of endotoxin. Circ Shock 1981;3:301-312
49. Groeneveld ABJ: Septic shock and multiple organ failure: Treatment with hemofiltration? Intensive Care Med 1990;16:489-490
50. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W: A circulating myocardial depressant substance in humans with septic shock: Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 1985;76:1539-1553
51. Reilly JM, Cunnion RE, Burch-Whitman C, Parker MM, Shelhamer JH, Parrillo JE: A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic shock. Chest 1989;95:1072-1085
52. Gomez A, Wang R, Unruh H, Light RB, Bose D, Chau T, Correa E, Mink S: Hemofiltration reverses left ventricular dysfunction during sepsis in dogs. Anesthesiology 1990;73:671-685
53. Ognibene FP, Parker MM, Natanson C, Shelhamer JH, Parrillo JE: Depressed left ventricular performance: Response to volume infusion in patients with sepsis and septic shock. Chest 1988;93: 903-910
54. Pasque MK, Van Trigt P, Pellom GL, Freedman BM, Wechsler AS: Assessment of the intrinsic contractile status of the heart during sepsis by monocardial pressure-dimension analysis. Ann Surg 1988;208:110-117
55. Coraim FJ, Coraim HP, Ebermann R, Stellwag FM: Acute respiratory failure after cardiac surgery: Clinical experience with the application of continuous arteriovenous hemofiltration. Crit Care Med 1986;14:714-718
56. Coraim F, Fasol R, Stellwag F, Wolner E: Continuous arteriovenous hemofiltration (CAVH) after cardiac surgery, in Siebert H-G, Mann H (eds): Continuous Arteriovenous Hemofiltration (CAVH). Basel, Karger, 1985, pp 116-124
57. Goldfarb RD, Lee KJ, Andrejuk T, Dziuban SW Jr: End-systolic elastance as an evaluation of myocardial function in shock. Circ Shock 1990;30:15-26
58. Benassayag C, Christeff N, Auclair M, Vernimen C, Carli-Vielle C, Nunez E, Carli A: Early released lipid-soluble cardiodepressant factor and elevated estrogenic substances in human septic shock. Eur J Clin Invest 1984;14:288-294
59. Lefer A: Interaction between myocardial depressant factor and vasoactive mediators with ischemia and shock. Am J Physiol 1987; 252:R193-R205
60. Wizemann V, Kramer W, Bechthold A, Thormann J: Acute effects of dialysis on myocardial contractility: Influence of cardiac status and calcium/potassium ratio. Contrib Nephrol 1986;52:66-68
61. Hegewisch S, Weh HJ, Hossfeld DK: TNF-induced cardiomyopathy. Lancet 1990;335:294-295
62. Cunnion RE, Parrillo JE: Myocardial dysfunction in sepsis: Recent insights. Chest 1989;95:941-947
63. Mallick AA, Ishizaka A, Stephens KE, Hatherill JR, Tazelaar HD, Raffin TA: Multiple organ damage caused by tumor necrosis factor and prevented by prior neutrophil depletion. Chest 1989;95: 1114-1120
64. Hörl WH, Haag-Weber M, Georgopoulos A, Block LH: Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci U S A 1990;87:6353-6357
65. Schützer KM, Haglund U, Falk A: Cardiopulmonary dysfunction in a feline septic shock model: Possible role of leukothenes. Circ Shock 1989;29:13-25
66. Roth DM, Lefer DJ, Hock CE, Lefer AM: Effects of peptide leukotrienes on cardiac dynamics in rat, cat and guinea pig hearts. Am J Physiol 1985;249:H477-H484
67. Michelassi F, Castorena G, Hill RD, Phil D, Lowenstein E, Watkins WD, Petkau AJ, Zapol WM: Effects of leukotrienes B4 and S C4 on coronary circulation and myocardial contractility. Surgery 1983;94:267-275
68. Letts LG, Piper PJ: The actions of leukotrienes C4 and C4 on guinea-pig isolated hearts. Br J Pharmacol 1982;76:169-176
69. Levi R, Burke JA, Corey EJ: SRS-A leukotrienes and immediate hypersensitivity reactions of the heart, in Samuelsson B, Paoletti R (eds): Leukotrienes and Other Lipooxygenase Products. New York, Raven Press, 1982, p 215